Long-term effects of aprepitant on tacrolimus pharmacokinetics in allogeneic hematopoietic stem cell transplantation

Abstract Background Aprepitant (APR), including intravenous fosaprepitant, is widely used as an antiemetic for highly emetogenic chemotherapy. APR is a moderate inhibitor and inducer of CYP3A4 and may alter the pharmacokinetics of concomitant drugs over an extended period. Tacrolimus (TAC), a key immunosuppressant after allogeneic hematopoietic stem cell transplantation (allo-HSCT), is primarily metabolized by CYP3A4. The long-term effects of APR on TAC pharmacokinetics remain unclear. Methods This retrospective observational study included patients receiving TAC for at least 28 days after allo-HSCT between January 2006 and April 2017. Patients were classified into APR-treated (APR(+)) and non-APR-treated (APR(-)) groups. During the 28-day observation period, patients switched from intravenous to oral TAC were censored at conversion to exclude the influence of bioavailability. TAC was administered by continuous intravenous infusion at 0.03 mg/kg/day starting on day − 1 and adjusted by therapeutic drug monitoring to maintain a target level of 15 ng/mL. APR was initiated between day − 8 and day 1 and was administered for up to 5 days, orally or intravenously. The concentration/dose (C/D) ratio was used as a surrogate marker of TAC clearance. Results A total of 64 patients were assessed for eligibility. Of these, 16 who received voriconazole or itraconazole were excluded, leaving 48 patients (28 APR(+), 20 APR(-)). Baseline characteristics and use of moderate CYP3A4 inhibitors did not differ between groups. From days 0–4, TAC C/D ratios were similar. In APR(+), C/D ratio decreased from day 5 to day 10, remained low for approximately 3 weeks, and returned to day 5 levels by day 28. C/D values on day 10 ± 1 and day 20 ± 1 were significantly lower than APR(-) ( P < 0.01). TAC doses in APR(+) increased from around day 5, reaching approximately 30% above day 4 ± 1 during days 10–25, then decreased. Conclusions Co-administration of TAC and APR increases TAC clearance from day 5, likely due to CYP3A4 induction, and the effect persists for approximately 3 weeks. The prolonged induction may relate to concomitant fluconazole use or longer half-life of TAC. Gradual TAC dose escalation of approximately 30% from day 5, with frequent monitoring for 2–3 weeks, may help maintain adequate exposure while minimizing GVHD and adverse effects.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Health Care and Sciences
Published
2026-11-17
DOI
https://doi.org/10.1186/s40780-026-00639-2
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Long-term effects of aprepitant on tacrolimus pharmacokinetics in allogeneic hematopoietic stem cell transplantation

Akira Honda, Tappei Takada, Yoshiyuki Ohno, Toyohito Oriyama et al.
Journal of Pharmaceutical Health Care and Sciences
Pharmacogenetics and Drug Metabolism
article

Long-term effects of aprepitant on tacrolimus pharmacokinetics in allogeneic hematopoietic stem cell transplantation

Akira Honda, Tappei Takada, Yoshiyuki Ohno, Toyohito Oriyama, Mineo Kurokawa, Kaoru Hitachi-Yuzawa, Takehito Yamamoto
article en

Abstract

Abstract Background Aprepitant (APR), including intravenous fosaprepitant, is widely used as an antiemetic for highly emetogenic chemotherapy. APR is a moderate inhibitor and inducer of CYP3A4 and may alter the pharmacokinetics of concomitant drugs over an extended period. Tacrolimus (TAC), a key immunosuppressant after allogeneic hematopoietic stem cell transplantation (allo-HSCT), is primarily metabolized by CYP3A4. The long-term effects of APR on TAC pharmacokinetics remain unclear. Methods This retrospective observational study included patients receiving TAC for at least 28 days after allo-HSCT between January 2006 and April 2017. Patients were classified into APR-treated (APR(+)) and non-APR-treated (APR(-)) groups. During the 28-day observation period, patients switched from intravenous to oral TAC were censored at conversion to exclude the influence of bioavailability. TAC was administered by continuous intravenous infusion at 0.03 mg/kg/day starting on day − 1 and adjusted by therapeutic drug monitoring to maintain a target level of 15 ng/mL. APR was initiated between day − 8 and day 1 and was administered for up to 5 days, orally or intravenously. The concentration/dose (C/D) ratio was used as a surrogate marker of TAC clearance. Results A total of 64 patients were assessed for eligibility. Of these, 16 who received voriconazole or itraconazole were excluded, leaving 48 patients (28 APR(+), 20 APR(-)). Baseline characteristics and use of moderate CYP3A4 inhibitors did not differ between groups. From days 0–4, TAC C/D ratios were similar. In APR(+), C/D ratio decreased from day 5 to day 10, remained low for approximately 3 weeks, and returned to day 5 levels by day 28. C/D values on day 10 ± 1 and day 20 ± 1 were significantly lower than APR(-) ( P < 0.01). TAC doses in APR(+) increased from around day 5, reaching approximately 30% above day 4 ± 1 during days 10–25, then decreased. Conclusions Co-administration of TAC and APR increases TAC clearance from day 5, likely due to CYP3A4 induction, and the effect persists for approximately 3 weeks. The prolonged induction may relate to concomitant fluconazole use or longer half-life of TAC. Gradual TAC dose escalation of approximately 30% from day 5, with frequent monitoring for 2–3 weeks, may help maintain adequate exposure while minimizing GVHD and adverse effects.

Journal of Pharmaceutical Health Care and Sciences
University of Tokyo Hospital (JP), The University of Tokyo (JP)
Good health and well-being
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon